Meshal AlSharafa

Mr. Meshal AlSharafa

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
SASamaa Abdullah
Samaa Abdullah
STSamar Thiab
Samar Thiab
AAAlaa AlMasud
Alaa AlMasud
MAMeshal AlSharafa
Meshal AlSharafa
AAAdel Ardakani
Adel Ardakani

12 December 2025 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SASamaa Abdullah
Samaa Abdullah
STSamar Thiab
Samar Thiab
AAAbeer A. Altamimi
Abeer A. Altamimi
AAAlaa AlMasud
Alaa AlMasud
MAMeshal AlSharafa
Meshal AlSharafa
IHImad Hamadneh
Imad Hamadneh

24 November 2025 in Journal of Science: Advanced Materials and Devices
Verified
Journal Article
Open access
MAManal Ahmed Awad
Manal Ahmed Awad
AHAwatif A. Hendi
Awatif A. Hendi
KOKhalid M. Ortashi
Khalid M. Ortashi
SASaad G. Alshammari
Saad G. Alshammari
HAHayat Althobaiti
Hayat Althobaiti
MAMaha M. Almoneef
Maha M. Almoneef

10 March 2026 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
SASamaa Abdullah
Samaa Abdullah
STSamar Thiab
Samar Thiab
AAAlaa AlMasud
Alaa AlMasud
MAMeshal AlSharafa
Meshal AlSharafa
AAAbeer Altamimi
Abeer Altamimi

11 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HAHanan Alyami
Hanan Alyami
FAFahd Abdullah Alshuweishi
Fahd Abdullah Alshuweishi
NBNadiah Baghdadi
Nadiah Baghdadi
MAMeshal AlSharafa
Meshal AlSharafa
AAAli Alqahtani
Ali Alqahtani
YAYazeed Abdullah Alshuweishi
Yazeed Abdullah Alshuweishi
Background: Cardiovascular risk in chronic kidney disease (CKD) remains high despite frequently normal conventional lipid parameters. The extent to which lipid patterns vary across CKD severity and metabolic complications remains incompletely characterized. Therefore, this study evaluated lipid patterns and their associations with renal function and CKD-related metabolic complications. Methods: This retrospective cross-sectional study included 229 CKD patients from the nephrology clinic at King Saud Medical City. Single-time-point laboratory data and clinical variables were extracted from medical records. Patients were stratified by KDIGO eGFR stage, uremia, and phosphate status. Lipid parameters were analyzed using nonparametric tests, multivariable regression, and ROC analysis. Results: Among 229 CKD patients, the most prevalent lipid abnormalities were low HDL-C (49.8%) and elevated remnant cholesterol (RC) (31.4%). HDL-C was reduced and RC increased with declining eGFR, while TC, LDL-C, and TG remained unchanged. In uremia, HDL-C remained reduced and RC increased, with additional reductions in TC and LDL-C, whereas TG did not differ. No significant lipid changes were observed with hyperphosphatemia. In multivariable analyses, HDL-C was positively associated with eGFR (β = 48.8, q = 0.003) and inversely associated with BUN (β = −14.3, q = 0.0014), while RC showed an inverse association with eGFR (β = −19.9, q = 0.0005) and a positive association with BUN (β = 3.37, q = 0.0315). These relationships remained independent of age, sex, BMI, smoking status, hypertension, and type 2 diabetes. ROC analysis further demonstrated the moderate discriminatory ability of HDL-C and RC for identifying CKD stages and uremia. Conclusions: Alterations in HDL-C and RC were independently associated with renal function and uremic status. These findings suggest that lipoprotein composition may reflect metabolic disturbances accompanying CKD progression.

30 April 2026 in BioNanoScience
Verified
Journal Article
Closed access
PDF file
SASamaa Abdullah
Samaa Abdullah
STSamar Thiab
Samar Thiab
AAAbeer Altamimi
Abeer Altamimi
AAAlaa AlMasud
Alaa AlMasud
MAMeshal AlSharafa
Meshal AlSharafa